|
|
|
|
|
 |
|
|
 |
Friday, January 14th, 2011
1:45pm (EST)
We are running a little late today because we wanted to see how the market would hold up going into the afternoon. The bulls have managed to push the indexes to fresh session highs after a slow start and the bulls look poised to capture another weekly win.
One interesting development, the Volatility Index (VIX, 15.73, down 0.66) is down more than 4% to a new three-week low. For those of you who are new or unfamiliar with the VIX, it is an index that measure fear in the market.
A rising VIX means the market is nervous while a falling VIX is good for the bulls. Usually, a reading under 20 indicates confidence and calm while a reading above 30 indicates the bears are in control.
There is one stock we would like to cover before we roll out today. Biodel (BIOD, $2.80, up $0.30) is up another 10% following yesterday 25% pop. We profiled this company in our Weekly Wrap on Sunday night and said it could be active this week. We aren’t ready to jump back into the name just yet but we are keeping our eyes on it.
As we head to press, the Dow is higher by 40 points to 11,772 while the S&P 500 is up 6 points to 1,290. The Nasdaq is showing an advance of 12 points to 2,747. We have more good news regarding our current trades so let’s get to the updates.
Posted in BioTech, Hot Stocks | Comments Off
Tuesday, January 11th, 2011
1:05pm (EST)
The bulls are pushing resistance once again after a number of companies beat earnings expectations which has helped offset weaker-than expected economic data. Although the market has moved slightly below its session highs, the momentum is there for the bulls to close above our price targets.
The Commerce Department said wholesale inventories fell 0.2% to $425.5 billion after increasing 1.9% in October. The suit-and-ties had expected a 1% rise in inventories. Elsewhere, concerns about the European debt crisis have been put on the back burner (again) after Portugal said it would not seek a bailout and Japan indicated it would buy euro zone bonds.
As far as specific stocks, Seattle Genetics (SGEN, $16.62, up $0.80) is getting a pop after its CEO gave an update on one of its cancer drugs and said he expects fast-track approval from the FDA this quarter. Additionally, the company said it also received an $8 million fee from Pfizer (PFE, $18.30, up $0.04) for rights to use its cancer-fighting antibody-drug technology.

Seattle Genetics could also receive more than $200 million in milestone and royalty payments for any products that stem from the agreement with Pfizer which will be responsible for developing and selling the products.
We covered both companies recently in our Weekly Wrap but we favor Seattle Genetics more than Pfizer. Although Pfizer pays a nice juicy dividend of 4.4%, we think shares of Seattle Genetics break $20 before Pfizer does.
As we head to press, the Dow is up 53 points to 11,690; the S&P is higher by 6 points to 1,276 while the Nasdaq is higher by 12 points to 2,720. We will be back Wednesday morning with a full update. Subscribers, check for the HOT updates inside the Members Area.
Tags: call options, momentum options, Momentum stocks, NASDAQ: SGEN, NYSE: PFE, pfe, SGEN Posted in BioTech, Company Commentary, Market Commentary | Comments Off
Sunday, December 26th, 2010
5:30pm (EST)
1. Market Summary
2. Seattle Genetics (SGEN) – Superior Product Leads to Value
3. Earnings
4. Weekly Wrap Portfolio Update
5. Week Ahead
= = = = = = = = = = = = = = =
1. Market Summary
The bulls continued their merry way as they scored another weekly win and pushed the major averages to fresh 2-year highs in the process. The strength (or surprise) came from the Financial sector which gained 2.5% on M&A (merger and acquisition) activity. The Regional banking stocks also joined in and had a solid week as traders looked for bargains and possible takeover targets.
To read more you must be a premium subscriber…
Tags: call option, how to trade options, momentum options trading, Momentum stocks, option picks, option stock picks, options alerts, options newsletter, options track record, put option, Seattle Genetics news, SGEN, stock options trading, volatile options Posted in BioTech, Weekly Wrap | Comments Off
Wednesday, December 8th, 2010
9:00am (EST)
There was a bull stampede that started on Tuesday’s open as the market ran higher to start the session on news the Bush tax cuts were going to be extended. However, the bears were the first to cross the finish line after the Democrats waffled on signing off on the cuts while in the same breath saying there was more work to do.
Against this uncertainty, the bulls failed to hold the momentum that had been so strong at the start but the good news is the breakout is intact. All three of the major averages we follow finished flat but not before touching fresh two-year highs.
The Dow fell 3 points to close at 11,359. We mentioned 3M’s (MMM, $84.19, down $2.69) downbeat forecast yesterday which accounted for 20 points to the negative for the index. The blue-chips traded to a high of 11,450 but the late day shenanigans pushed the Dow below our 11,400 closing target. Support is at 11,200-11,000.
The S&P 500 gained a point and settled at 1,223 but surged to a high of 1,235. We were looking for a close above 1,230 but the breakout confirmed we should trend to 1,250 over the near-term. Support is 1,200.
The Nasdaq added 3 points and finished at 2,598 but rallied to 2,623 before finishing just below our 2,600 target once again. We still feel a run to 2,700 is still possible with an outside shot at 3,000. The bears are focused on getting Tech back down below 2,500.
Orexigen Therapeutics (OREX, $4.67, HALTED) is going to have a huge open this morning after a Food and Drug Administration (FDA) panel recommended approval for Contrave, a weight loss drug that will help fight the battle against obesity.
We first profiled Orexigen, along with Vivus (VVUS, $7.80, up $0.75) in early 2008 and we have been keeping track of these two companies ever since. Long time subscribers know we tend to favor Vivus more because we think their “diet” drug, Qnexa, is safer and has less side effects. Vivus also has a stronger pipeline.
Look for both stocks to hit double-digits today as Orexigen is trading at $11+ in pre-market while Vivus is pushing $10.
Futures are pointing towards a slightly higher open this morning. Dow futures are up 6, S&P 500 futures are up 2 while the Nasdaq 100 futures are higher by 7 points.
We have a ton of information to cover in our Members Area this morning, including our thoughts on Research In Motion (RIMM, $62.12, down $1.21), which we added to our Watch List. Subscribers, check for the updates.
Tags: bear market, binary options, bull market, call option, how to trade options, Momentum stocks, Nasdaq: OREX, Nasdaq: VVUS, NYSE: MMM, option investments, option picks, option trading, options mentoring, options trading service, OREX, put option, stock market, stock market options, VVUS Posted in BioTech, Hot Stocks, Market Analysis | Comments Off
Friday, October 22nd, 2010
12:40pm (EST)
It been a busy week and a lot of interesting developments are happening in the market right now. The bulls came into the week looking to extend September and October’s gains but got a wakeup call on Tuesday when the Dow fell below 11,000. However, the bounce from Tuesday has been impressive and the bulls are on track for another weekly gain.
The bears may be out of ammo and could have used their last bullets on Tuesday as the bulls appear poised to break through the April highs. We have been all over the current market’s move like grass on dirt and we mentioned this morning if we get a break above resistance the bulls could blow the roof off the house.
So, what catalysts are the bulls banking on to help them break on through to the other side?
Besides earnings, two important dates to circle on your calendar will be November 2 and 3. This is when we get the mid-term U.S. elections and the Fed will meet to talk about QE2 or when or how much they will actually start to flood the world with dollars.
The Republicans will be looking to take control of the house while Wall Street wants a another massive quantitative easing program that will continue to weaken the dollar and drive the market up; anything less than $100 billion from the Fed will be a disappointment and could be the one thing that derails the current rally.
We are also expecting a HUGE announcement concerning one Biotech stock whose fate lies in the hands of the FDA. It is a $4 stock and we see shares going past $10 if its diabetes drug is approved or, if not, a 50% haircut and a drop below $2. This news is due out by next Friday and it still not too late to get into this trade. We urge you to take a look at it.
As you can see, the next few weeks will likely shape the trading landscape for the rest of 2010 and we should have an even clearer trend. Of course, the current trend has been up but if we get a blow-off rally after breaking resistance then there will be plenty of opportunities for triple-digits returns.
We have used the “trend is your friend” thesis this month to book some solid gains this week after a rocky September. We were betting for one last test of the lows but the market surged after its August swoon which is also when we started to deploy our option straddle and strangle trades.

We talked about Amylin Pharmaceuticals (AMLN, $11.33, down $0.15) fall from $20 to $10 earlier this week and we did a video on how you could have used the information from our Watch List AND our option trading manual, How to Trade Option on Momentum Stocks, to make gains of 400%-700% if you would have deployed a strangle option trade on Amylin. The course also contains another book, Momentum Stocks Watch List, which covers dozens of sectors and over 600 stocks.
The video will be released this weekend and will be the third video that will be covering the manual. Folks, we are giving you the blueprint to find some spectacular trades over the next few weeks and we will be doing another video on how to play the indexes for option trades.
If we get into November with the market breaking out to new highs, or a correction is about to take place, then you will know exactly how to play the volatility. Remember, we are also offering a free 1-month subscription to our exclusive Members Area with any course purchase by the end of October which means you only have 8 more days to hit us up on this offer (a $129 value).
We wanted to go over all of this because we truly believe we are going to see some incredible opportunities to make more triple-digit returns over the next month or two.
As we head to press, the Dow is down 31 points to 11,115 while the S&P is flat at 1,180. The Nasdaq is up by 11 points to 2,471.
We have a couple of trade updates to talk about before we head out to enjoy the weekend but we will be here Monday morning with a full update and a possible NEW TRADE. We have closed one trade this week for a 135% return and we are putting in a stop to protect another one after closing half of it for a 100% return.
This means we have some room to add one or two new ideas which is perfect for the action that will be going down over the next few weeks. Subscribers, check for the updates and enjoy your weekend.
Tags: binary options, call option, put option Posted in BioTech, Earnings, Trading Psychology | Comments Off
|
|
|  | | | |
Seattle Genetics (SGEN) Making Noise
Tuesday, January 11th, 2011
1:05pm (EST)
The bulls are pushing resistance once again after a number of companies beat earnings expectations which has helped offset weaker-than expected economic data. Although the market has moved slightly below its session highs, the momentum is there for the bulls to close above our price targets.
The Commerce Department said wholesale inventories fell 0.2% to $425.5 billion after increasing 1.9% in October. The suit-and-ties had expected a 1% rise in inventories. Elsewhere, concerns about the European debt crisis have been put on the back burner (again) after Portugal said it would not seek a bailout and Japan indicated it would buy euro zone bonds.
As far as specific stocks, Seattle Genetics (SGEN, $16.62, up $0.80) is getting a pop after its CEO gave an update on one of its cancer drugs and said he expects fast-track approval from the FDA this quarter. Additionally, the company said it also received an $8 million fee from Pfizer (PFE, $18.30, up $0.04) for rights to use its cancer-fighting antibody-drug technology.
Seattle Genetics could also receive more than $200 million in milestone and royalty payments for any products that stem from the agreement with Pfizer which will be responsible for developing and selling the products.
We covered both companies recently in our Weekly Wrap but we favor Seattle Genetics more than Pfizer. Although Pfizer pays a nice juicy dividend of 4.4%, we think shares of Seattle Genetics break $20 before Pfizer does.
As we head to press, the Dow is up 53 points to 11,690; the S&P is higher by 6 points to 1,276 while the Nasdaq is higher by 12 points to 2,720. We will be back Wednesday morning with a full update. Subscribers, check for the HOT updates inside the Members Area.
Tags: call options, momentum options, Momentum stocks, NASDAQ: SGEN, NYSE: PFE, pfe, SGEN
Posted in BioTech, Company Commentary, Market Commentary | Comments Off